Although various SGLT2 inhibitors have been shown to have significant protective effects on the kidneys and cardiovascular system in patients with diabetes, recent data has shown that DAPA is also beneficial for those individuals with non-diabetic kidney disease [30]. This evidence concerns the gene SLC5A2 and diabetes mellitus.